A Randomized Phase II Study to Evaluate the Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma

Trial Profile

A Randomized Phase II Study to Evaluate the Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 29 Feb 2016

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin; Ifosfamide; Paclitaxel
  • Indications Penile cancer
  • Focus Therapeutic Use
  • Acronyms PENILANE
  • Most Recent Events

    • 24 Feb 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 10 Feb 2015 Planned End Date changed from 1 May 2016 to 1 Oct 2017 as reported by ClinicalTrials.gov record.
    • 10 Feb 2015 Planned primary completion date changed from 1 Apr 2016 to 1 Sep 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top